Trinity Biotech (NASDAQ:TRIBD)
Historical Stock Chart
From Sep 2019 to Sep 2024
Trinity Biotech Names GraficaGroup Agency of Record
Grafica Supporting Clinical Diagnostic Instrumentation Marketing in Hemostasis,
Immunodiagnostics, and Rapid HIV Testing
CHESTER, N.J., June 21 /PRNewswire/ -- Today, GraficaGroup officially
announced that Trinity Biotech USA has named the Chester-based company as its
new Agency of Record. After reviewing several agencies in the first quarter of
2005, Trinity selected Grafica to help develop and communicate a new brand
position to support an overall marketing-communications campaign. Grafica will
provide advertising, media, trade-show support, and interactive services for
Trinity, as the company continues its growth and expansion within multiple
clinical diagnostic markets, including hemostasis, immunodiagnostics, specialty
chemistry, and rapid HIV testing.
"After establishing our U.S. headquarters in New Jersey this year, we sought an
agency that could help position the Trinity brand and tell the Trinity story to
our key markets," said Philippe Gadal, Ph.D., U.S. CEO, Trinity Biotech.
"Grafica proved they possess the requisite creative talent and branding
experience that Trinity needs to effectively promote our products, technology,
and service, as we continue growing business and market share in the United
States."
Grafica began its relationship with Trinity by developing a new brand position,
print advertisement, and tagline: Diagnostics Driven by Life.(R) The campaign
starts in June in several publications targeting clinical diagnostic
professionals and public health officials. The new Trinity campaign conveys how
Trinity understands the pressures of life in the laboratory, while
communicating the well-known brands in the company's portfolio, which includes
AMAX Destiny(TM) (coagulation), NEXGEN Four (infectious disease), and the
Uni-Gold(TM) Recombigen(R) rapid HIV test.
"Trinity's products greatly improve the way diagnostic laboratories function,
and its Uni-Gold product is the fastest and simplest test for detecting HIV
infection," said Debra Taeschler, President and CEO, GraficaGroup. "We at
Grafica look forward to integrating the brand position we developed for Trinity
across multiple media, including the Web, which we believe will help Trinity
assume market leadership in hemostasis, infectious disease, clinical chemistry,
and rapid HIV testing."
About Trinity Biotech USA
With its U.S. Corporate Headquarters based in Berkeley Heights, New Jersey,
Trinity Biotech Inc. is a wholly owned subsidiary of Trinity Biotech plc
(NASDAQ:TRIB). With World Headquarters in Bray, Ireland, Trinity Biotech plc
was established in 1992. Through an acquisition-growth strategy, Trinity has
acquired companies with expertise in the development and commercialization of
both instrumentation and reagents primarily servicing the infectious disease,
hemostasis, specialty chemistry, and HIV diagnostics markets. Additional
information about Trinity is available on the company Web site at
http://www.trinitybiotech.com/.
About GraficaGroup
GraficaGroup is a full-service, fully integrated advertising agency led by
professionals from Madison Avenue who continue to craft brand -- and
relationship-building campaigns from just off of Main Street in Chester, New
Jersey. Grafica (http://www.grafica.com/) provides both traditional and online
marketing campaigns, including broadcast, print, out of home, direct mail,
point of purchase, email, and Web-site design and development. Grafica also
offers media planning and buying, search-engine optimization, database
management, and public relations. Clients include AT&T, Cathedral Healthcare
System, First Morris Bank and Trust, Horizon Blue Cross Blue Shield of New
Jersey, Jackson Hewitt Tax Service, the New Jersey Board of Public Utilities,
the New Jersey Office of the Attorney General, PSE&G, Singer Nelson Charlmers,
Synchronoss Technologies, and Wells Fargo Home Mortgage.
Forward-Looking Statements
Forward-looking statements in this release are made pursuant to the "safe
harbor" provision of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States Food and
Drug Administration and other agencies, the impact of competitive products,
product development commercialization and technological difficulties, and other
risks detailed in the Company's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Dana Thomas
Trinity Biotech USA
908.898.1500 x7010
Mark Devaney
GraficaGroup
908.879.2169 x115
DATASOURCE: GraficaGroup
CONTACT: Dana Thomas of Trinity Biotech USA, +1-908-898-1500 ext. 7010,
; or Mark Devaney of GraficaGroup, +1-908-879-2169,
ext. 115,
Web site: http://www.grafica.com/
http://www.trinitybiotech.com/